Bristol-Myers Squibb revenue falls as expected
US drug major Bristol-Myers Squibb (NYSE: BMY) reported results for the second quarter of 2013 showing that sales were down 9% year on year at $4.05 billion following the US patent expiration of Avapro/Avalide (irbesartan) in March 2012 and Plavix (clopidogrel) in May 2012. Forbes analysts had predicted the 9% revenue drop after revenue has fallen in the past four quarters.
Generally Accepted Accounting Principles (GAAP) diluted earnings per share (EPS) were down 16% to $0.32 and non-GAAP diluted EPS was down 8% to $0.44. Analysts quoted by the Wall Street Journal had expected earnings of $0.44 cents on revenues of $4.04 billion. The paper also said the company’s shares were up less than 1% in premarket trade.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze